COVID-19疫苗接种后需住院治疗的月经过多风险:一项全国性病例对照研究
该研究基于法国国家健康数据系统,纳入2021年5月12日至2022年8月31日因月经过多住院的15-50岁非妊娠女性4610例及匹配对照89375例,采用条件logistic回归分析。结果显示,与未接种女性相比,完成初级疫苗接种后1-3个月内月经过多住院风险升高(OR 1.20,95%CI 1.07-1.35),但初级接种3个月后及加强针后未见风险升高。
要点
- 初级COVID-19疫苗接种后1-3个月内月经过多住院风险升高(OR 1.20,95%CI 1.07-1.35)。
- 该关联在居住于最贫困市镇的女性(OR 1.28,95%CI 1.07-1.52)及未使用激素避孕的女性(OR 1.28,95%CI 1.11-1.48)中更明显。
- 初级接种3个月后及加强针接种后未发现月经过多住院风险升高。
核心结论
- 研究结果提示,初级COVID-19 mRNA疫苗接种后三个月内月经过多风险升高。
- 初级接种3个月后及加强针接种后未发现风险升高。
研究设计与样本
- 研究为基于法国国家健康数据系统的全国性病例对照研究。
- 病例为2021年5月12日至2022年8月31日期间因月经过多住院的15-50岁非妊娠女性,按年龄、居住地、社会剥夺指数和避孕使用情况随机匹配最多30名对照。
- 共纳入4610例病例和89375名匹配对照,中位年龄42岁。
- 采用条件logistic回归模型估计风险,调整社会人口学特征、合并症、医疗使用指标和近期SARS-CoV-2感染。
主要发现
- 与未接种女性相比,末次初级疫苗接种在1-3个月内的女性月经过多住院风险升高(OR 1.20,95%CI 1.07-1.35)。
- 该关联在居住于最贫困市镇的女性中更明显(OR 1.28,95%CI 1.07-1.52),在未使用激素避孕的女性中亦更明显(OR 1.28,95%CI 1.11-1.48)。
- 假设因果关系,估计法国有103例(95%CI 54-196)月经过多住院病例可归因于初级疫苗接种。
- 初级接种3个月后及加强针接种后未发现月经过多住院风险升高。
关键数值与推荐
- 初级疫苗接种后1-3个月内月经过多住院风险OR 1.20(95%CI 1.07-1.35)。
- 最贫困市镇女性中OR 1.28(95%CI 1.07-1.52)。
- 未使用激素避孕的女性中OR 1.28(95%CI 1.11-1.48)。
- 归因于初级疫苗接种的月经过多住院病例估计为103例(95%CI 54-196)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 vaccination has been inconsistently associated with an increased risk of heavy menstrual bleeding in previous studies. This study aimed to assess the risk of heavy menstrual bleeding requiring hospital care following COVID-19 vaccination according to the number of doses received and the time elapsed since vaccination. METHODS: Using comprehensive data of the French National Health Data System, we carried out a case-control study. Non-pregnant 15-50 years old women who had a hospital discharge diagnosis of heavy menstrual bleeding between May 12, 2021, and August 31, 2022 (cases) were randomly matched to up to 30 controls of same age, place of residence, social deprivation index, and contraceptive use profile at the date of case hospital admission (index date). Conditional logistic regression models were used to estimate the risk of hospital care for heavy menstrual bleeding associated with primary or booster doses and delay since last COVID-19 vaccination at index date, adjusting for socio-demographic characteristics, comorbidities, healthcare use indicators, and recent SARS-CoV-2 infection. RESULTS: A total of 4610 cases and 89,375 matched controls were included (median age, 42 years). Compared to unvaccinated women, the risk of hospital care for heavy menstrual bleeding was increased in those having received a last dose of primary vaccination in the preceding 1-3 months (Odds Ratio, 1.20 [95% confidence interval, 1.07-1.35]). This association was marked among women residing in the most deprived municipalities (1.28 [1.07-1.52]) and those who were not using hormonal contraception (1.28 [1.11-1.48]). Assuming a causal relationship, a total of 103 cases [54-196] were estimated to be attributable to primary vaccination in France. CONCLUSION: These findings provide evidence of an increased risk of heavy menstrual bleeding during the three-month period following primary COVID-19 mRNA vaccination. No increased risk was found beyond 3 months after primary vaccination nor following booster doses.
引用
- Botton J, Bertrand M, Jabagi MJ, et al. Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study. Vaccine. 2024. PMID: 39226788. doi:10.1016/j.vaccine.2024.126252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。